Back to results
US 12,415,861 B2Granted
Anti C-MET antibodies
AssigneeCentessa Pharmaceuticals (UK) Limited
InventorWilliam James Jonathan Finlay
Life of this patent
Estimating the term…
Abstract
Provided herein are antibody molecules that bind specifically to C-MET and related nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.
Claims19
An anti-C-MET antibody or an antigen-binding portion thereof, wherein the antibody comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein
- (a) the VH region amino acid sequence comprises HCDR1 of GYTFTSYTMH (SEQ ID NO:
- 34), HCDR2 of MGIINPSGGSTSYAQKFQG (SEQ ID NO:
- 35) and HCDR3 of QEITTEFDY (SEQ ID NO:
- 36);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYANSYLH (SEQ ID NO:
- 37), LCDR2 of RGSTRES (SEQ ID NO:
- 38) and LCDR3 of QQSKSEPLT (SEQ ID NO:
- 39);
- (b) the VH region amino acid sequence comprises HCDR1 of GYTFTSYTMH (SEQ ID NO:
- 34), HCDR2 of MGWINPSGGLANYAQKFQG (SEQ ID NO:
- 54) and HCDR3 of SEITTDFDY (SEQ ID NO:
- 55);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVDSYANSYLH (SEQ ID NO:
- 51), LCDR2 of RGSTRES (LCDR2;
- SEQ ID NO:
- 38) and LCDR3 of QQSKSEPLT (SEQ ID NO:
- 39);
- (c) the VH region amino acid sequence comprises HCDR1 of GYTFTSYTMH (SEQ ID NO:
- 34), HCDR2 of MGWINPSGGSTSYAQKFQG (SEQ ID NO:
- 40) and HCDR3 of QEITTEFDY (SEQ ID NO:
- 36);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYANSYLH (SEQ ID NO:
- 37), LCDR2 of RGSTRES (SEQ ID NO:
- 38) and LCDR3 of QQSKSEPLT (SEQ ID NO:
- 39);
- (d) the VH region amino acid sequence comprises HCDR1 of GYTFTSYAMH (SEQ ID NO:
- 41), HCDR2 of MGWINPSGGSTSYAQKFQG (SEQ ID NO:
- 40) and HCDR3 of QEITTEFDY (SEQ ID NO:
- 36);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYANSYLH (SEQ ID NO:
- 37), LCDR2 of RGSTRES (SEQ ID NO:
- 38) and LCDR3 of QQSKSEPLT (SEQ ID NO:
- 39);
- (e) the VH region amino acid sequence comprises HCDR1 of GYTFTSYTMH (SEQ ID NO:
- 34), HCDR2 of MGWINPNGGSTSYAQKFQG (SEQ ID NO:
- 42) and HCDR3 of QEITTEFDY (SEQ ID NO:
- 36);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVSSYANSYLH (SEQ ID NO:
- 37), LCDR2 of RGSTRES (SEQ ID NO:
- 38) and LCDR3 of QQSKSEPLT (SEQ ID NO:
- 39);
- (f) the VH region amino acid sequence comprises HCDR1 of GYIFTSYSMH (SEQ ID NO:
- 43), HCDR2 of MGWINPSNGLANYAQKFQG (SEQ ID NO:
- 44) and HCDR3 of QEITTEFDI (SEQ ID NO:
- 45);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVESYAQSYLH (SEQ ID NO:
- 46), LCDR2 of RGSTRES (SEQ ID NO:
- 38) and LCDR3 of QQSKSDPLT (SEQ ID NO:
- 76);
- (g) the VH region amino acid sequence comprises HCDR1 of GYIFTSYTMH (SEQ ID NO:
- 48), HCDR2 of MGWINPNGGLASYAQKFQG (SEQ ID NO:
- 49) and HCDR3 of SEITTEQDY (SEQ ID NO:
- 50);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVDSYANSYLH (SEQ ID NO:
- 51), LCDR2 of RGSTRES (SEQ ID NO:
- 38) and LCDR3 of QQSKESPLT (SEQ ID NO:
- 47);
- or
- (h) the VH region amino acid sequence comprises HCDR1 of GYIFTSYTMH (SEQ ID NO:
- 48), HCDR2 of MGWINPNGGSTSYAQKFQG (SEQ ID NO:
- 42) and HCDR3 of QEITTEFDY (SEQ ID NO:
- 36);
- and the VL region amino acid sequence comprises LCDR1 of RASQSVESYANSYLH (SEQ ID NO:
- 52), LCDR2 of RGSTRES (SEQ ID NO:
- 38) and LCDR3 of QQYGSEPLT (SEQ ID NO:
- 53).
63 more elements
Dependencies are inferred from the claim text.